Stock DNA
Pharmaceuticals & Biotechnology
CNY 12,217 Million (Large Cap)
15.00
NA
4.18%
-0.13
21.89%
3.35
Revenue and Profits:
Net Sales:
1,126 Million
(Quarterly Results - Mar 2026)
Net Profit:
247 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.41%
0%
-3.41%
6 Months
-5.88%
0%
-5.88%
1 Year
-15.13%
0%
-15.13%
2 Years
-18.96%
0%
-18.96%
3 Years
24.4%
0%
24.4%
4 Years
63.24%
0%
63.24%
5 Years
103.45%
0%
103.45%
Henan Lingrui Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.25%
EBIT Growth (5y)
22.12%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
1.09
Tax Ratio
12.98%
Dividend Payout Ratio
82.09%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
29.45%
ROE (avg)
18.32%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
3.35
EV to EBIT
13.98
EV to EBITDA
12.80
EV to Capital Employed
3.69
EV to Sales
2.97
PEG Ratio
2.34
Dividend Yield
4.18%
ROCE (Latest)
26.41%
ROE (Latest)
21.89%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
1,126.10
1,020.80
10.32%
Operating Profit (PBDIT) excl Other Income
262.90
259.20
1.43%
Interest
0.80
0.50
60.00%
Exceptional Items
0.80
-0.40
300.00%
Consolidate Net Profit
247.40
216.70
14.17%
Operating Profit Margin (Excl OI)
233.40%
230.50%
0.29%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 10.32% vs 13.95% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 14.17% vs 13.87% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,814.80
3,455.50
10.40%
Operating Profit (PBDIT) excl Other Income
923.40
798.90
15.58%
Interest
0.70
0.70
Exceptional Items
-7.10
0.30
-2,466.67%
Consolidate Net Profit
762.40
722.60
5.51%
Operating Profit Margin (Excl OI)
215.50%
209.10%
0.64%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 10.40% vs 5.44% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 5.51% vs 27.20% in Dec 2024
About Henan Lingrui Pharmaceutical Co., Ltd. 
Henan Lingrui Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






